Breaking News
Get 50% Off 0
Nederlandse versie beschikbaar
Wilt u liever naar Investing.com's Nederlandse editie?
🧠 Smart money is quietly buying these undervalued gems
See Undervalued Stocks
Close

AbbVie Inc (ABBV)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow AbbVie's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
208.41 -0.12    -0.06%
- Closed. Currency in USD
After Hours
208.42
+0.01
+0.00%
- Real-time Data
Type:  Equity
Market:  United States
  • Volume: 3,865,338
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 205.55 - 209.79
AbbVie 208.41 -0.12 -0.06%

ABBV User Rankings

 
Users ranking according to the performance of their sentiments for the AbbVie Inc stock.
RankUsernameTotalClosedWinningWin %Chg. %
1neal macdougall88787.5+61.56%
2Fadil Nemr333100+29.98%
3Jose Azorin111100+25.9%
4Peggy Schmeink111100+25.37%
5Tim F111100+24.88%
6Henk VS111100+23.97%
7Harry Jay111100+23.85%
8wojtek wolinski111100+23.56%
9Anthony Massaad111100+23.27%
10Ismail Mohd Yusof111100+22.22%
11Sam Traveller111100+21.85%
12Tiget_ksa111100+20.84%
13jh kim222100+20.55%
14Fernando Jacinto33266.67+20.35%
15Ап Нап111100+19.44%
16up upp111100+19.41%
17Chai Xhjo111100+19.38%
18Evan LaFrance111100+18.86%
19path murugiah322100+18.69%
20javime melero111100+18.58%
21Rayme Marrero333100+17.89%
22Ahmed Bahous111100+17.86%
23boom sirawit111100+17.36%
24JUNO LAWRANCE222100+16.78%
25Teo Viv111100+16.77%
26pawlew osiodaisd33266.67+16.56%
27Eduardo Freire111100+16.48%
28Аристарх Сигизмундович222100+16.47%
29pimon pawan111100+16.39%
30Kanida Sawatbamrung111100+16.13%
31Антон Авсенин111100+16.02%
32Juan Rodriguez111100+15.95%
33José Caldeira111100+15.7%
34준열 한111100+15.58%
35Xavier Marbà22150+15.56%
36Mindenek Atyja Egyetlen111100+15.51%
37Денис Михайлов111100+15.4%
38Rajesh Chodhari111100+15.04%
39Luigi RD222100+15.01%
40Александр Соколов111100+14.96%
41Toto Piscopo111100+14.42%
42Андрей Ефимов44375+14.37%
43Joe kim111100+14.33%
44Vasile Hupca111100+14.28%
45Chayada Punsombut111100+14.13%
46Adam Pavlik111100+14.08%
47Giacomo Niccolai111100+14.01%
48Antonio Faraone111100+13.76%
49Александр Матичев222100+13.58%
50omyma kafi111100+13.49%
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

ABBV Comments

Write your thoughts about AbbVie Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Ron West
Ron West Feb 18, 2026 7:32PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
230 resistance, resistance, resistance!
Ron West
Ron West Feb 13, 2026 11:38AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Break through 230 resistance again.
Ron West
Ron West Jan 27, 2026 2:46PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Another try at breaking through 230! Looking good!
Ron West
Ron West Jan 23, 2026 7:14PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
If you can, hang in there, it's still very good.
Hülagü Yalınkılıç
Hülagü Yalınkılıç Jan 08, 2026 4:11PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
This development comes just a day after Abbvie (NYSE:ABBV) denied it was in discussions to purchase Revolution Medicines, following rumors published in the Wall Street Journal. These acquisition rumors have created significant volatility in Revolution’s stock, though shares have generally trended upward in recent days. Revolution Medicines, which focuses on developing targeted therapies for cancer treatment, has become an attractive target in the pharmaceutical industry’s ongoing consolidation trend, as larger companies seek to bolster their drug pipelines through acquisitions.
Hülagü Yalınkılıç
Hülagü Yalınkılıç Jan 08, 2026 4:11PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Revolution Medicines (NASDAQ:RVMD) stock rose 5% Thursday following a Financial Times report that Merck (NYSE:MRK) is in talks to acquire the biotech company. Unlock the hottest news by upgrading to InvestingPro - get 55% off today According to the FT, citing people familiar with the matter, Merck has been pursuing an acquisition of the Redwood City-based biotech firm, though a deal has not been finalized. Any potential agreement would be at least several weeks away, sources indicated. The report also suggested that other large pharmaceutical companies remain interested in Revolution Medicines, and another suitor might ultimately prevail. However, a transaction is not guaranteed at this stage. This development comes just a day after Abbvie (NYSE:ABBV) denied it was in discussions to purchase Revolution Medicines, following rumors published in the Wall Street Journal. These acquisition rumors have created significant volatility in Revolution’s stock, though shares have generally trended upward in recent days. Revolution Medicines, which focuses on developing targeted therapies for cancer treatment, has become an attractive target in the pharmaceutical industry’s ongoing consolidation trend, as larger companies seek to bolster their drug pipelines through acquisitions.
Ron West
Ron West Dec 31, 2025 9:37PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
230 - Happy New Year!
Ron West
Ron West Dec 26, 2025 10:15AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
let's break through the 230 resistance.
Ron West
Ron West Dec 05, 2025 11:47AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
continued upward movement - I'm sraying put.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email